What is TriSalus Life Sciences, Inc.'s G&A?

TriSalus Life Sciences, Inc. (TLSI) reported G&A of $5.45M in Q1 2026.

How has TriSalus Life Sciences, Inc.'s G&A changed year-over-year?

TriSalus Life Sciences, Inc.'s G&A increased by 3.9% year-over-year, from $5.25M to $5.45M.

What is the long-term trend for TriSalus Life Sciences, Inc.'s G&A?

Over 4 years (2021 to 2025), TriSalus Life Sciences, Inc.'s G&A has grown at a 63.5% compound annual growth rate (CAGR), from $3.04M to $21.73M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

TriSalus Life Sciences, Inc. TLSI G&A

G&A at other companies

AngioDynamicsANGO

$10.72M+2.2%

InfuSystem HoldingsINFU

$14.8M-3.3%

Tactile Systems TechnologyTCMD

$23.04M+15.2%

Cullinan Therapeutics, Inc.CGEM

$11.57M-14.5%

Corvus PharmaceuticalsCRVS

$3.7M+49.9%

Nektar TherapeuticsNKTR

$13.44M-44.8%

Other financials

Income statement

See full

Revenue$8.9M-2.9%

Gross profit$7.7M0.0%

Operating income-$8.4M-14.8%

Net income$1.5M+115%

EPS (diluted)$0.03+108%

Balance sheet

See full

Cash & equivalents$56.6M+324%

Total debt$33.1M+4.4%

Total equity$12.8M+137%

Total assets$71.0M+148%

Cash flow

See full

Operating cash flow-$6.5M-44.0%

CapEx$141.0K-81.3%

Free cash flow-$6.6M-26.0%

Valuation

See full

Market cap$279.45M+49.6%

Enterprise value$255.97M+33.6%

P/S6.2×+1.0×

Profitability

See full

Gross margin85.1%-0.5pp

Operating margin-62.4%-16.8pp

Net margin-60.9%-13.4pp

FCF margin-45.2%-16.8pp

Returns & leverage

See full

Return on equity253.3%—

Debt / equity2.6×—

Current ratio5.8×+3.6×

Where this comes from

Reported directly by TriSalus Life Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s G&A?: TriSalus Life Sciences, Inc. (TLSI) reported G&A of $5.45M in Q1 2026.
How has TriSalus Life Sciences, Inc.'s G&A changed year-over-year?: TriSalus Life Sciences, Inc.'s G&A increased by 3.9% year-over-year, from $5.25M to $5.45M.
What is the long-term trend for TriSalus Life Sciences, Inc.'s G&A?: Over 4 years (2021 to 2025), TriSalus Life Sciences, Inc.'s G&A has grown at a 63.5% compound annual growth rate (CAGR), from $3.04M to $21.73M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.